Jaknat Tablet contains Tofacitinib 5 mg, a Janus kinase (JAK) inhibitor indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adult patients who have had an inadequate response or intolerance to conventional disease-modifying antirheumatic drugs (DMARDs). Tofacitinib works by selectively inhibiting JAK enzymes, which play a key role in the signaling pathways involved in the inflammatory and immune responses. By modulating these pathways, Jaknat Tablet helps reduce inflammation, pain, and joint damage associated with autoimmune conditions. The recommended dosage and duration of therapy should be determined by a healthcare professional based on the patient’s clinical condition and response to treatment. Patients should be monitored for potential adverse effects, including infections, hematologic abnormalities, liver enzyme elevations, and lipid profile changes. Caution is advised in patients with a history of serious infections, malignancies, or hepatic impairment. Jaknat Tablet is contraindicated in patients with known hypersensitivity to Tofacitinib or any of its excipients. Regular laboratory evaluations and clinical assessments are essential to ensure safety and efficacy during therapy. This medication should be used under strict medical supervision with adherence to prescribed dosing regimens.